# Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial

> **NCT04847349** · NA · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 54 (actual)

## Conditions studied

- Covid19

## Interventions

- **DIETARY_SUPPLEMENT:** OL-1, standard dose
- **DIETARY_SUPPLEMENT:** OL-1, high dose
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT04847349
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-13
- **Primary completion:** 2021-11-01
- **Final completion:** 2022-01-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-02-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847349, "Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04847349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*